吲哚布芬对比华法林用于房颤患者的抗凝治疗效果及护理分析

Efficacy and Nursing Experience of Indobufen Versus Warfarin for Anticoagulant Therapy in Patients with Atrial Fibrillation

目的:探讨吲哚布芬对比华法林用于房颤患者抗凝治疗的效果和护理分析。方法:选择2016年2月-2017年7月在福建医科大学附属第二医院收治的137例房颤患者,随机分为研究组(70例)和对照组(67例)。两组均给予常规护理,对照组给予口服华法林5 mg,研究组给予口服吲哚布芬片。比较两组患者血浆中D-二聚体水平、脑栓塞发生率、出血发生率。结果:研究组和对照组治疗后血浆中D-二聚体水平分别为(3.0±0.5)mg/L和(2.9±0.7)mg/L,比较差异无统计学意义(t=0.965,P=0.168)。研究组和对照组患者脑栓塞发生率分别为11.43%和7.46%,比较差异无统计学意义(字2=0.628,P=0.428)。研究组出血率为1.43%,显著低于对照组的8.96%,差异有统计学意义(字2=3.982,P=0.046)。结论:吲哚布芬用于预防房颤患者脑栓塞的效果与华法林相似,但拥有更低的出血发生率,对房颤患者而言,吲哚布芬是一种可行的替代方案。

Objective:To investigate the efficacy and nursing experience of Indobufen versus Warfarin for anticoagulant therapy in patients with atrial fibrillation.Method:A total of 137 patients with atrial fibrillation admitted to the Second Affiliated Hospital of Fujian Medical University from February 2016 to July 2017 were randomly divided into study group(70 cases) and control group(67 cases).Both groups were given routine nursing.The control group was given oral Warfarin 5 mg,and the study group was given oral Indobufen Tablets.The plasma levels of D-dimer,the incidence of cerebral embolism and the hemorrhage were compared between the two groups.Result:The level of D-dimer in plasma in the study group and the control group were(3.0±0.5)mg/L and(2.9±0.7)mg/L,respectively,and the difference was not significant(t=0.965,P=0.168).The incidences of cerebral thrombosis were 11.43% and 7.46% in the study group and the control group respectively,and the difference was not significant( 字2=0.628,P=0.428).The hemorrhage rate in the study group was 1.43%,which was significantly lower than 8.96% in the control group( 字2=3.982,P=0.046).Conclusion:Indobufen was similar to warfarin in preventing cerebral embolism in patients with atrial fibrillation,but it has a lower incidence of bleeding.For patients with atrial fibrillation,Indobufen is a viable alternative.